Recent data from the FDA's 2025 National Youth Tobacco Survey reveal a significant public health achievement: youth tobacco use in the United States has fallen to historically low levels. This progress is not accidental; it results from years of prevention efforts, stricter age restrictions, public education, and a collective commitment to keeping tobacco and nicotine products away from minors. However, this success should not breed complacency. The same data show that 1.7% of students still report current nicotine pouch use, and any youth use remains unacceptable. Prevention must continue to be a cornerstone of nicotine regulation and marketing.
While youth use declines, a persistent challenge remains: cigarette smoking among adults. According to the CDC, cigarette smoking is the leading cause of preventable death in the United States. Millions of adults continue to smoke despite decades of warnings and cessation campaigns. For these individuals, complete cessation is the optimal health outcome, but for those who cannot or will not quit, access to accurate information about scientifically substantiated smoke-free alternatives is crucial.
In this context, the FDA's recent action on ZYN nicotine pouches is a landmark. After rigorous scientific review, the agency issued modified risk orders for 20 ZYN products, allowing them to be marketed with a claim that using ZYN instead of cigarettes reduces the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. This does not mean these products are safe or suitable for non-nicotine users. Rather, it empowers adult smokers with evidence-based information about relative risks, a key component of a harm reduction approach.
The FDA's decision underscores a vital distinction: nicotine products are addictive and not risk-free, and they are not intended as cessation therapies. But policy should recognize the substantial difference in risk between combustible cigarettes and smoke-free alternatives. The latest youth data demonstrate that these goals are not mutually exclusive. Between 2022 and 2025, youth use of tobacco products, including e-cigarettes, declined. Nicotine pouch use among youth remained low and stable, indicating that a marketplace with FDA-authorized adult alternatives does not undermine youth prevention efforts.
Dr. Matthew Holman, vice president and chief science and regulatory strategy officer for PMI U.S., emphasizes that smoke-free products are exclusively for adults 21 and older. PMI U.S. has implemented responsible marketing practices: advertising features individuals aged 35 or older, websites require online age verification, and social media use is limited to age-restricted platforms. The company does not use influencers or product placement. These measures are part of a broader 10-point plan for underage prevention, which includes retail support, monitoring, and cooperation with FDA enforcement.
The path forward requires collective action from regulators, manufacturers, retailers, and public health leaders. The United States has made remarkable strides in reducing youth tobacco use. Now, it must apply the same rigor to addressing adult smoking. A mature tobacco policy should both prevent youth initiation and help adult smokers transition to better alternatives. These are not conflicting objectives; they are complementary components of a comprehensive public health strategy.
